Last reviewed · How we verify
NCT03600623
Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
EARLY_PHASE1 trial testing Folfirinox in Locally Advanced Pancreatic Cancer in 25 participants. Terminated before completion.
30 July 2020
Quick facts
| Lead sponsor | University of Alabama at Birmingham |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 25 September 2017 |
| Primary completion | 30 July 2020 |
| Estimated completion | 31 July 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Folfirinox (folfirinox) — full drug profile →
- Gemcitabine nab-Paclitaxel
Conditions studied
- Locally Advanced Pancreatic Cancer — all drugs for Locally Advanced Pancreatic Cancer →
- Borderline Pancreatic Inoperable Cancer — all drugs for Borderline Pancreatic Inoperable Cancer →
- Pancreatic Cancer — all drugs for Pancreatic Cancer →
Sponsor
University of Alabama at Birmingham
Who can join
Adults 18 to 75, any sex, with Locally Advanced Pancreatic Cancer or Borderline Pancreatic Inoperable Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will implement a new treatment regimen for patients with advanced and inoperable pancreatic cancer using chemotherapy combinations of Folfirinox or gemcitabine-nab paclitaxel (abraxane) followed by a short course of high dose radiation called Stereotactic Body Radiation Therapy (SBRT). While the chemotherapy is standard of care, the strategy of adding SBRT has not been investigated. An increase in the percentage of patients who can proceed to have surgery to remove their disease is anticipated with this approach.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03600623
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Folfirinox
Trials testing the same drug.
- NCT07340567 — Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test · Phase 3 · not yet recruiting
- NCT06068023 — The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer. · recruiting
- NCT05132504 — Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer · Phase 2 · recruiting
- NCT04431258 — ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study · Phase 1, PHASE2 · completed
- NCT04897854 — Timing of Start of systemIc Treatment for Asymptomatic Metastasized Pancreatic Cancer · Phase 3 · unknown
Other recruiting trials for Locally Advanced Pancreatic Cancer
Currently open trials in the same condition.
- NCT04276857 — Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer · NA · recruiting
- NCT06944587 — A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer · recruiting
- NCT06494514 — NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line · NA · recruiting
- NCT05975593 — MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial · NA · recruiting
- NCT05653453 — Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatme · Phase 3 · recruiting
Other University of Alabama at Birmingham trials
Trials by the same sponsor.
- NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
- NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
- NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
- NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
- NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03600623 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
- Last refreshed: 18 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03600623.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing